ResMed Inc.
RMD | NYSE
$224.78
+$1.17 (+0.52%)
Sep 22, 2026, 12:26 PM ET · Market open
Company Profile
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Michael J. Farrell | Chief Executive Officer & Chairman |
| Aaron Bloomer | Chief Financial Officer |
| Alastair Robertson | Chief Information Officer |
| Michael Rider | Chief Legal Officer & Secretary |
| Vered Keisar | Chief People Officer |
| Yvonne-Katrin Pucknat | Chief Marketing Officer |
| Brett A. Sandercock | Advisor |
| Jim Ellis | Chief Compliance Officer |
| Justin Leong | Chief Product Officer |
| Peter C. Farrell | Founder, Chair Emeritus & Non-Executive Director |
| Sallilyn Schwartz | Chief Investor Relations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Sep 01, 2026 | 8-K | Current Report |
| Aug 17, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 10-K | Annual Report |
| Aug 11, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 07, 2026 | 144 | Filing |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 4 | Filing |
| Aug 05, 2026 | 144 | Filing |
ResMed Inc.
| Country | United States |
| IPO Date | Jun 1, 1995 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 11,370 |
| CEO | Michael J. Farrell |
Contact Details
9001 Spectrum Center Boulevard San Diego,
California 92123 United States
Stock Details
| Ticker Symbol | RMD |
| Exchange | NYSE |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000943819 |
| CUSIP Number | 761152107 |
| ISIN Number | US7611521078 |
| SIC Code | 3841 |
Recent News
- 1 day ago / marketbeat.comResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
- 7 days ago / barrons.comSleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
- 7 days ago / seekingalpha.comWall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'
- 7 days ago / seekingalpha.comResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 7 days ago / zacks.comIs This the Right Time to Retain Resmed Stock in Your Portfolio?
- 12 days ago / seekingalpha.comResMed: A Significant Upside Despite The Perceived Risk
- 14 days ago / 247wallst.comThe IRS Lets You Send Your RMD Straight to Charity and Skip the Tax Entirely. These 3 ETFs Replace the Income You Gave Away
- 19 days ago / prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
- 1 month ago / 247wallst.comThe IRS Makes You Sell Whether the Market Is Up or Down. These 3 ETFs Fund the RMD Without Touching a Share
- 1 month ago / globenewswire.comResmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
Add to Watchlist
Select watchlists to add or remove RMD